Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56353 | 0.95 | PLA2G2A (0.61) | PLA2G2AKMT2AMEN1PLA2G4BNPC1 | |
| SCHEMBL13461246 | 0.93 | PLA2G2A (0.73) | PLA2G2AKMT2APLA2G4BTP53TSHR | |
| SCHEMBL89376 | 0.91 | PLA2G2A (0.66) | PLA2G2AKMT2AMEN1TP53TSHR | |
| SCHEMBL23352170 | 0.91 | PLA2G2A (0.64) | PLA2G2AKMT2AMEN1TP53TSHR | |
| SCHEMBL89430 | 0.89 | PLA2G2A (0.54) | PLA2G2AKMT2AMEN1PLA2G4BRAB9A | |
| SCHEMBL3374820 | 0.89 | PLA2G2A (0.54) | PLA2G2AKMT2AMEN1PLA2G4B | |
| SCHEMBL2175665 | 0.87 | PLA2G2A (0.53) | PLA2G2AKMT2AMEN1PLA2G4BTP53 | |
| SCHEMBL27994057 | 0.87 | PLA2G2A (0.59) | PLA2G2AKMT2AMEN1TP53TSHR | |
| SCHEMBL3488958 | 0.87 | MEN1 (0.75) | PLA2G2AKMT2AMEN1PLA2G4BTP53 | |
| SCHEMBL28529167 | 0.86 | PLA2G2A (0.67) | PLA2G2AKMT2AMEN1PLA2G4BTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | PLA2G2A 2842/4885KMT2A 921/4885MEN1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.